Page last updated: 2024-08-21

erythromycin and Soft Tissue Neoplasms

erythromycin has been researched along with Soft Tissue Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM1
Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB1

Trials

2 trial(s) available for erythromycin and Soft Tissue Neoplasms

ArticleYear
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
    Cancer, 2007, Jun-01, Volume: 109, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erythromycin; Humans; Ifosfamide; Remission Induction; Sarcoma; Soft Tissue Neoplasms; Time Factors

2007
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids

2000